Royal United Hospitals in Bath has become the first site in both the UK and Europe to recruit a patient to the VERONICA oncology study that will test the efficacy of venetoclax to treat breast cancer.
This study is lead by pharmaceutical company Hoffmann-La Roche with Covance, a contract research organization.
Ventoclax is used to treat chronic lymphocytic leukemia. The study aims to compare the efficacy of venetoclax in combination with fulvestrant, a hormonal therapy drug used to treat advanced breast cancer, compared with fulvestrant alone in women with Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor (HER2)-negative, inoperable, locally advanced, or Metastatic Breast Cancer (MBC). Participants recruited into this trial must have experienced disease recurrence or progression during or after treatment with CDK4/6i therapy for at least eight weeks.
As of 15 January, there are 31 worldwide sites activated. Globally, there are 16 patients enrolled across the UK, USA, Canada and Australia.The study is also due to open in Germany. The estimated completion date for the study is October 2022, and it is aiming to recruit 100 patients.
Ifan Jones, Senior Research Delivery Manager of the West of England CRN said “This is a fantastic result for the Oncology team at Royal United Hospitals (RUH), Bath and testament to the hard work of the team. Achieving a UK first recruit shows that RUH has an effective research infrastructure so that studies are set up and recruited into quickly.”
Dr Rebecca Bowen, RUH Consultant Medical Oncologist, who is leading the research study at the hospital, said “We are delighted to be participating in such an interesting and important trial, allowing our patients to access treatments which may improve outcomes in metastatic breast cancer further”.
Dr Tim Craft, Director of Research and Innovation, RUH, Bath said "This is great news for our patient and shows that we continue to strive to offer the opportunity to participate in leading edge research even when we are treating advanced disease. Well done to our oncology research team."
This study is lead by pharmaceutical company Hoffmann-La Roche with Covance, a contract research organization.
Ventoclax is used to treat chronic lymphocytic leukemia. The study aims to compare the efficacy of venetoclax in combination with fulvestrant, a hormonal therapy drug used to treat advanced breast cancer, compared with fulvestrant alone in women with Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor (HER2)-negative, inoperable, locally advanced, or Metastatic Breast Cancer (MBC). Participants recruited into this trial must have experienced disease recurrence or progression during or after treatment with CDK4/6i therapy for at least eight weeks.
As of 15 January, there are 31 worldwide sites activated. Globally, there are 16 patients enrolled across the UK, USA, Canada and Australia.The study is also due to open in Germany. The estimated completion date for the study is October 2022, and it is aiming to recruit 100 patients.
Ifan Jones, Senior Research Delivery Manager of the West of England CRN said “This is a fantastic result for the Oncology team at Royal United Hospitals (RUH), Bath and testament to the hard work of the team. Achieving a UK first recruit shows that RUH has an effective research infrastructure so that studies are set up and recruited into quickly.”
Dr Rebecca Bowen, RUH Consultant Medical Oncologist, who is leading the research study at the hospital, said “We are delighted to be participating in such an interesting and important trial, allowing our patients to access treatments which may improve outcomes in metastatic breast cancer further”.
Dr Tim Craft, Director of Research and Innovation, RUH, Bath said "This is great news for our patient and shows that we continue to strive to offer the opportunity to participate in leading edge research even when we are treating advanced disease. Well done to our oncology research team."
Comments
Post a Comment